Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 5, Pages 615-618Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.5.615
Keywords
atherosclerosis; CGS23425; coronary heart disease; GC-1; KB-141; KB-2115; thyromimetics
Categories
Ask authors/readers for more resources
Background: Whereas many new targets for drug discovery have been identified from new biology, such as that from the Human Genome Project, some targets have been known for decades but have not been exploited. Objective: One such target, selective thyromimetics, is reviewed from a historical perspective and in the light of recent developments. Methods: The history of thyromimetics in atherosclerosis and dyslipidaemia is reviewed as the background to the recent publication of the first human data on a new selective thyromimetic, KB-2115 (eprotirome). Conclusion: The published data provide proof of concept/mechanism, opening the way to larger studies in a wider range of subjects and in combination with statins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available